|
Advertise About
Live
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%
TSX24,847▲ +0.44%
S&P 5005,612▲ +0.31%
Gold$3,342▼ −0.19%
BTC$108,240▲ 1.82%
WTI$78.40▲ +1.12%
USD/CAD1.3612▼ −0.08%
Silver$33.80▲ +0.62%
Uranium$92.50▲ +2.44%

Two New TSX-V and CSE Listings Raise $34M in November 2026

A uranium exploration junior and an AI-powered MedTech firm debut on Canadian exchanges this week, together pulling in $34 million as the TSX Composite navigates a 0.76% pullback.

Editorial independence
·
Reviewed by editorial team
·
Sources cited & linked
·
Not investment advice
4 min read
· Editorial Policy
Key Takeaways
  • Athabasca Atomic Corp. (AAC.V) raised $18M CAD at $0.75 on the TSX-V, backed by a $4.5M Sprott Asset Management cornerstone investment in uranium exploration.
  • NovaMind Diagnostics (NVMD) debuted on the CSE at $2.00, raising $16M CAD for its AI retinal-scan platform targeting early Alzheimer’s and Parkinson’s detection.
  • Insider lockup expiries — mid-March 2027 for AAC.V and May 11, 2027 for NVMD — are the key liquidity dates retail investors should monitor closely.
  • Both listings are accessible to retail investors at low board-lot costs ($75 and $200 CAD respectively), but both companies remain pre-revenue at time of listing.

Canadian equity markets welcomed two fresh listings this week despite a broader risk-off tone, with the TSX Composite sitting at 36,170 (−0.76%) on November 11, 2026. The newcomers — a northern uranium explorer and a domestic AI diagnostics company — collectively raised $34 million CAD at their respective IPO prices, signalling that sector-specific appetite remains healthy even as macro headwinds persist.

Athabasca Atomic Corp. (AAC.V) — TSX Venture Exchange

Athabasca Atomic Corp. began trading on the TSX-V on November 10, 2026, under the ticker AAC.V, priced at $0.75 per share and raising $18 million CAD through a 24-million-unit offering. The Saskatoon-based junior explorer holds a contiguous 142,000-hectare land package in Saskatchewan’s eastern Athabasca Basin — ground that sits within 40 kilometres of Cameco’s McArthur River operation, the world’s highest-grade uranium mine. The company’s flagship Clearwater Lake zone returned assays of up to 3.2% U₃O₈ over 6.4 metres in a 2025 drill program, results that drew early institutional attention ahead of the listing.

The offering was led by Canaccord Genuity as sole bookrunner, with Haywood Securities and PI Financial rounding out the syndicate. Notably, Sprott Asset Management anchored the deal with a $4.5 million cornerstone commitment — a signal of conviction from one of the most closely watched names in uranium investing. Retail investors can purchase shares on the TSX-V through any standard Canadian brokerage account; the minimum board lot is 100 shares, making entry accessible at roughly $75 CAD for a board lot.

Insider lockup provisions under the TSX-V escrow policy place seed shares under a 36-month graduated escrow, with 25% released at 6 months post-listing and the remainder in equal tranches every six months thereafter. IPO shares held by principals are subject to a 4-month statutory hold expiring in mid-March 2027. Retail investors should mark that date as the first meaningful insider liquidity event.

NovaMind Diagnostics Inc. (NVMD) — Canadian Securities Exchange

NovaMind Diagnostics Inc. made its market debut on the CSE under ticker NVMD on November 11, 2026, raising $16 million CAD at an IPO price of $2.00 per share through an 8-million-share offering. The Toronto-based company has built a proprietary AI platform — branded ClarityDx — that analyzes retinal scans to detect early-stage neurodegenerative conditions including Alzheimer’s disease and Parkinson’s disease with a claimed sensitivity of 91% in its Phase II clinical validation study. The platform is designed to integrate directly with optometry clinic workflows, targeting Canada’s network of approximately 7,000 licensed optometrists as its primary distribution channel.

Raymond James Ltd. served as lead underwriter, with Echelon Capital Markets as co-manager. The deal attracted participation from two unnamed Canadian pension sub-funds disclosed in the prospectus as “Selling Restriction Exempt” institutional buyers, absorbing a combined $5 million of the raise. NovaMind has a pre-existing commercial pilot agreement with FYidoctors, Canada’s largest optometry group, covering 22 clinic locations — a partnership that provides near-term revenue visibility ahead of Health Canada regulatory clearance, which management targets for Q3 2027.

All officer and director shares are subject to a 6-month contractual lockup negotiated with Raymond James, expiring May 11, 2027. At $2.00 per share, a board lot costs $200 CAD, making this one of the more accessible MedTech debuts on the CSE this year. Investors should note that NovaMind remains pre-revenue; cash from the offering is budgeted to fund operations through Q1 2028.

Company Ticker Exchange Sector IPO Price Funds Raised Lead Underwriter Insider Lockup Expiry
Athabasca Atomic Corp. AAC.V TSX-V Uranium Exploration $0.75 CAD $18M CAD Canaccord Genuity Mid-March 2027
NovaMind Diagnostics Inc. NVMD CSE AI / MedTech $2.00 CAD $16M CAD Raymond James Ltd. May 11, 2027

Both listings arrive at a moment when Canadian investors are weighing near-term index weakness against sector-specific catalysts. Uranium continues to benefit from federal nuclear energy commitments, while AI diagnostics represents one of the fastest-growing verticals in Canadian biotech venture capital. As always with early-stage listings, position sizing and due diligence on prospectus risk factors remain essential before committing capital.

James Okoro

Boreal Markets Staff

Contributing writer at Boreal Markets.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Boreal Markets and SmallCap Communications Inc. are not registered investment advisers. Always conduct your own due diligence before making investment decisions.

The Boreal Brief

Canadian markets intelligence every morning before the open. Free.